GO
Loading...

CVS Health Corp

More

  • Final Glance: Drug Benefits companies Monday, 26 Jan 2015 | 6:04 PM ET

    NEW YORK— Shares of some top drug benefits companies were mixed at the close of trading:. CVS Health Corp. rose$. 39 or. 4 percent, to $101.01. Express Scripts Holding Co. fell$. 05 or. 1 percent, to $84.75.

  • Final Glance: Drugstore companies Monday, 26 Jan 2015 | 6:04 PM ET

    CVS Health Corp. rose$. 39 or. 4 percent, to $101.01. Rite Aid rose$. 14 or 1.9 percent, to $7.65. Walgreen Boots Alliance Inc. rose$. 25 or. 3 percent, to $75.84.

  • Jan 26- Pharmacy benefits manager EnvisionRx said on Monday it reached an agreement to provide its customers with Gilead Sciences Inc's hepatitis C drugs on an exclusive basis, the latest Gilead victory in a market share battle with AbbVie over their new treatments for the liver destroying virus. EnvisionRx said Gilead's Sovaldi and its newer two-drug...

  • Final Glance: Drug Benefits companies Friday, 23 Jan 2015 | 6:04 PM ET

    NEW YORK— Shares of some top drug benefits companies were mixed at the close of trading:. CVS Health Corp. rose$. 34 or. 3 percent, to $100.62. Express Scripts Holding Co. fell$. 19 or. 2 percent, to $84.80.

  • Final Glance: Drugstore companies Friday, 23 Jan 2015 | 6:04 PM ET

    CVS Health Corp. rose$. 34 or. 3 percent, to $100.62. Rite Aid rose$. 06 or. 8 percent, to $7.51. Walgreen Boots Alliance Inc. fell$. 43 or. 6 percent, to $75.59.

  • Final Glance: Drug Benefits companies Thursday, 22 Jan 2015 | 6:05 PM ET

    NEW YORK— Shares of some top drug benefits companies were up at the close of trading:. CVS Health Corp. rose$. 78 or. 8 percent, to $100.28. Express Scripts Holding Co. rose $1.45 or 1.7 percent, to $84.99.

  • Final Glance: Drug Benefits companies Wednesday, 21 Jan 2015 | 6:01 PM ET

    NEW YORK— Shares of some top drug benefits companies were up at the close of trading:. CVS Health Corp. rose $1.13 or 1.1 percent, to $99.50. Express Scripts Holding Co. rose$. 06 or. 1 percent, to $83.54.

  • Final Glance: Drugstore companies Wednesday, 21 Jan 2015 | 6:01 PM ET

    CVS Health Corp. rose $1.13 or 1.1 percent, to $99.50. Rite Aid unchanged at $7.32. Walgreen Boots Alliance Inc. fell$. 46 or. 6 percent, to $75.59.

  • Aetna Inc. said Friday that it's reached a deal with Gilead bringing discounts for Sovaldi and Harvoni, which have list prices of about $84,000 and $94,000, respectively, for a course of treatment. Aetna's decision follows moves by two huge prescription benefit managers, Express Scripts Holdings Co. and CVS Health Corp., to wring big discounts from makers of a...

  • Investors are watching closely to see how insurers decide to cover these drugs, which cost tens of thousands of dollars per treatment, after AbbVie Inc started a competitor to Gilead Sciences' breakthrough hepatitis C treatment. Express Scripts, the largest pharmacy benefit manager in the United States, dropped Gilead Sciences hepatitis C drugs from its main...

  • Jan 8- Health insurer Anthem Inc on Thursday said it reached a deal under which Gilead Sciences Inc's hepatitis C drug Harvoni will be the primary treatment for patients infected with the most common strain of the liver-destroying virus. Last month, AbbVie Inc began sales of a competing drug, Viekira Pak, at a similar list price. Express Scripts Holding Co, the...

  • Jan 8- AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira. U.S. health regulators approved Viekira Pak, AbbVie's all-oral treatment for hepatitis C in December. AbbVie's newly approved regimen is also cheaper than Gilead's...

  • Flu boosts drug store sales, but others take a hit Wednesday, 7 Jan 2015 | 10:24 AM ET
    A woman receiving a flu vaccination in San Pablo, Calif.

    This year’s flu season is shaping up to be as bad as expected. That's good news for drug stores, but insurers and others could suffer.

  • Cramer Remix: Buy into this weakness Tuesday, 6 Jan 2015 | 7:03 PM ET
    Jim Cramer on Mad Money.

    The recent selloffs have been ugly, but "Mad Money" host Jim Cramer thinks you can buy these stocks into the red arrows.

  • Lightning Round: Don't fool around with this one Tuesday, 6 Jan 2015 | 6:51 PM ET

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Cramer's 10 lessons learned from 2014 Monday, 5 Jan 2015 | 6:10 PM ET
    Traders on the floor of the New York Stock Exchange.

    On a down day in the market, Jim Cramer thinks this is the perfect time to review the silly preconceptions of 2014.

  • The euro fell to a near nine-year low against the dollar of $1.18605 on the EBS platform, tumbling on political uncertainty in Greece and fears of a possible Greek exit from the euro zone. The Greece question was front and center for Paul Nolte, portfolio manager at Kingsview Asset Management. "What you've done is thrown that entire area up for grabs, it will be very...

  • Jan 5- CVS Health Corp, one of the largest U.S. managers of drug benefits, said it would give preferred status to the hepatitis C treatments from Gilead Sciences and cover a new competing treatment from AbbVie Inc only as an exception. The latest salvo in the battle to grab market share for new all-oral treatments for the liver-destroying hepatitis C virus follows...

  • Gilead fights back: CVS deal sends shares soaring Monday, 5 Jan 2015 | 1:05 PM ET
    Pedestrians walk by a CVS store in San Francisco.

    Gilead Sciences' hepatitis C drugs, Sovaldi and Harvoni, will get exclusive coverage on several plans from CVS/Caremark.

  • Midday movers: Exxon Mobil, Chevron, Hess & more Monday, 5 Jan 2015 | 12:56 PM ET

    Some of Monday's midday movers: